GlassScriptPhysician profile
Nickolas D Scherzer
NPI 1790247542
$9,167.68
in general payments reported to CMS, 2019-2025
17 companies · $4,652 in 2025
The $4,652 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,323 · 2022: $670 · 2023: $598 · 2024: $1,925 · 2025: $4,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,383 · Travel and Lodging: $2,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,383.13 |
| Travel and Lodging | $2,792.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,276.78 | 2021-2025 | Solyx Sis System, Axonics, Spaceoar Vue System - 10ml |
| Teleflex LLC | $2,074.36 | 2024-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $1,870.41 | 2025 | |
| Coloplast Corp | $728.15 | 2023-2025 | Titan |
| Medtronic, INC. | $525.71 | 2022-2025 | Interstim, Altaviva |
| Axonics, INC. | $203.94 | 2024 | Axonics, Bulkamid |
| Abbvie INC. | $164.79 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $67.73 | 2024-2025 | Gemtesa |
| Myovant Sciences INC. | $53.88 | 2022 | |
| Photocure INC | $45.83 | 2022-2025 | Cysview |
| Angiodynamics, INC. | $27.98 | 2025 | Nanoknife |
| Pfizer INC. | $25.22 | 2024 | |
| Telix Pharmaceuticals | $24.17 | 2025 | Illuccix |
| Myriad Genetic Laboratories, INC. | $22.24 | 2024 | Prolaris |
| Urogen Pharma, INC. | $22.02 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $20.09 | 2025 | Xyosted |
| Blue Earth Diagnostics | $14.38 | 2025 | Posluma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickolas Scherzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.